copper palmitoyl heptapeptide 14 vs ghk cu AHK-CU vs. GHK-CU – Neurogan Health Palmitoyl Tripeptide copper palmitoyl heptapeptide 14 vs

Potential risks Serious risks and adverse events include: Allergic reaction to the medications or dye used in the injection Shoulder infection Depigmentation of the skin around the injection site (a whitening of the skin) Local fat atrophy around the injection site (thinning of the skin) Rupture of a tendon located in the path of the injection Nerve damage near the shoulder joint Bleeding at the injection site In addition to the above, corticosteroid injections increase the risk of: High blood pressure High blood sugar Decreased immune function Decrease in bone mineral density Bone infection (osteonecrosis) Reproductive hormone imbalance Metabolic changes (eg, increased appetite, weight gain, and fluid retention) These risks are typically associated with higher doses of corticosteroids, multiple injections, and for people with underlying medical conditions such as diabetes and heart problems

Status: Research phase No completed human RCTs Not FDA-approved SC injection or oral (research only) Caveat: BPC-157 is under review at the FDA's July 2026 peptide advisory panel and is currently restricted for compounding

One customer wrote that he sought a lab report from the seller, only to be ignored

For a lot of folks, anecdotal evidence seems to be enough. The scientific evidence tells a different story